Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

NCT06046040 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT06046040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 31, 2024
Completion date
January 31, 2042
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castrate-resistant prostate cancer (mcrpc)